|
Physiomics PLC on Wednesday said its personalised dosing software project has now obtained the key approvals needed to progress with its observational trial. The Oxfordshire, England-based mathematical modelling company that supports oncology drug development, said its personalised dosing software, Pecision Risk Evaluation and G-CSF Dosing for Chemotherapy-Induced Neutropenia Tool, PREDICT-ONC, has now received both regulatory and ethical approval. The firm says that it can now proceed with the PREDICT-ONC observational trial. Shares in Physiomics rose 9.7% to 0.85 pence on Wednesday afternoon in London. Physiomics said its software was initially developed to help clinicians with chemotherapy dosing decisions, but the results of a Partner study in January 2023 indicated that the software could be utilised in support of the dosing of drug granulocyte colony-stimulating factor. GCSF is a drug used routinely to counteract toxic chemotherapy effects on white blood cells, a condition called neutropenia. The firm said recruitment for the observational trial can begin imminently, projecting completion between October and December this year. ‘The project...will recruit breast cancer patients undergoing standard of care GCSF treatment onto an observational clinical trial in order to predict and measure the effect treatment has on neutropenia’, said the firm. It added that data gained from the trial, which is being conducted in partnership with Beyond Blood Diagnostics Ltd and Blackpool Teaching Hospitals NHS Foundation Trust will support the refinement and evaluation of the software. Physiomics Chief Executive Officer Peter Sargent said: ‘Physiomics and our partners are thrilled to have now obtained approval to proceed with the PREDICT-ONC observational trial. We had initially planned to start this trial last summer, but due to delays in the approval process that were out of our hands, approval has only now been obtained. ‘However, due to the hard work of the project team, including recruitment of a research nurse and proactive identification of potential patients, we predict that these delays will have minimal impact on the overall timelines and final readout of the project. We at Physiomics are excited to start receiving the data generated from this trial, so we can continue development of our personalised dosing software’. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
